Alpha Biopharma Announces Completion of its EVEREST Phase II/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System Metastases ...Middle East

Zorifertinib is a next generation EGFR-TKI with full Blood Brain Barrier penetration targeting EGFRm+ NSCLC patients with CNS metastases Top-line data from the study are expected around the end of 2022 SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Alpha Biopharma, a developer of innovative...

Hence then, the article about alpha biopharma announces completion of its everest phase ii iii clinical study of zorifertinib in non small cell lung cancer patients with central nervous system metastases was published today ( Thursday 25/08/2022 - 05:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Alpha Biopharma Announces Completion of its EVEREST Phase II/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System Metastases )

Also on site :

• Russia-Ukraine war: List of key events, day 1,428
• Thrash Metal Icon Reveals Truth About Final Album of 43-Year-Old Band
• Christina Haack Stuns in Bikini With Boyfriend on Tropical Getaway